Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) vs Adult obesity prevalence (age-standardized, %) in Andorra

In 2024, measles-containing-vaccine second-dose (MCV2) immunization coverage (%) in Andorra stood at 97%, against 17.1% for adult obesity prevalence (age-standardized, %).

Change the pair

Compare different indicators

The series

Over time

Andorra, spaced by time. Both series are in %, so they share one axis; the legend names each line.

Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %)

Unit: % · 61 observations

2 series · one axis

Estimates are listed as such in the table below

Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %): AndorraMeasles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %). 2 indicators on one axis: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%), Adult obesity prevalence (age-standardized, %). 61 observations from 1990 to 2025, ranging from 0% to 97%. Latest values: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 96% (2025); Adult obesity prevalence (age-standardized, %) 17.1% (2024). % 0 20 40 60 80 100 1990 1996 2002 2008 2014 2020 96% 17% Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) Adult obesity prevalence (age-standardized, %)
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %): AndorraMeasles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %). 2 indicators on one axis: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%), Adult obesity prevalence (age-standardized, %). 61 observations from 1990 to 2025, ranging from 0% to 97%. Latest values: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 96% (2025); Adult obesity prevalence (age-standardized, %) 17.1% (2024). % 0 30 60 90 120 1990 1996 2002 2008 2014 2020 96% 17% Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) Adult obesity prevalence (age-standardized, %)
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %): AndorraMeasles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %). 2 indicators on one axis: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%), Adult obesity prevalence (age-standardized, %). 61 observations from 1990 to 2025, ranging from 0% to 97%. Latest values: Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 96% (2025); Adult obesity prevalence (age-standardized, %) 17.1% (2024). % 0 30 60 90 120 1990 1996 2002 2008 2014 2020 96% 17% Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) Adult obesity prevalence (age-standardized, %)
View the underlying data
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) and Adult obesity prevalence (age-standardized, %): Andorra
Indicator Period Type Value
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2025 Estimate 96%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2024 Estimate 97%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2023 Estimate 96%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2022 Estimate 96%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2021 Estimate 97%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2020 Estimate 93%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2019 Estimate 97%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2018 Estimate 95%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2017 Estimate 94%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2016 Estimate 90%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2015 Estimate 88%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2014 Estimate 90%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2013 Estimate 91%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2012 Estimate 89%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2011 Estimate 82%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2010 Estimate 86%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2009 Estimate 82%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2008 Estimate 86%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2007 Estimate 80%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2006 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2005 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2004 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2003 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2002 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2001 Estimate 0%
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) 2000 Estimate 0%
Adult obesity prevalence (age-standardized, %) 2024 Estimate 17.1%
Adult obesity prevalence (age-standardized, %) 2023 Estimate 17.1%
Adult obesity prevalence (age-standardized, %) 2022 Estimate 17.1%
Adult obesity prevalence (age-standardized, %) 2021 Estimate 17.1%
Adult obesity prevalence (age-standardized, %) 2020 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2019 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2018 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2017 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2016 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2015 Estimate 17%
Adult obesity prevalence (age-standardized, %) 2014 Estimate 16.9%
Adult obesity prevalence (age-standardized, %) 2013 Estimate 16.9%
Adult obesity prevalence (age-standardized, %) 2012 Estimate 16.8%
Adult obesity prevalence (age-standardized, %) 2011 Estimate 16.7%
Adult obesity prevalence (age-standardized, %) 2010 Estimate 16.6%
Adult obesity prevalence (age-standardized, %) 2009 Estimate 16.4%
Adult obesity prevalence (age-standardized, %) 2008 Estimate 16.2%
Adult obesity prevalence (age-standardized, %) 2007 Estimate 15.9%
Adult obesity prevalence (age-standardized, %) 2006 Estimate 15.6%
Adult obesity prevalence (age-standardized, %) 2005 Estimate 15.3%
Adult obesity prevalence (age-standardized, %) 2004 Estimate 14.9%
Adult obesity prevalence (age-standardized, %) 2003 Estimate 14.6%
Adult obesity prevalence (age-standardized, %) 2002 Estimate 14.2%
Adult obesity prevalence (age-standardized, %) 2001 Estimate 13.9%
Adult obesity prevalence (age-standardized, %) 2000 Estimate 13.5%
Adult obesity prevalence (age-standardized, %) 1999 Estimate 13.2%
Adult obesity prevalence (age-standardized, %) 1998 Estimate 12.8%
Adult obesity prevalence (age-standardized, %) 1997 Estimate 12.5%
Adult obesity prevalence (age-standardized, %) 1996 Estimate 12.2%
Adult obesity prevalence (age-standardized, %) 1995 Estimate 11.9%
Adult obesity prevalence (age-standardized, %) 1994 Estimate 11.7%
Adult obesity prevalence (age-standardized, %) 1993 Estimate 11.4%
Adult obesity prevalence (age-standardized, %) 1992 Estimate 11.2%
Adult obesity prevalence (age-standardized, %) 1991 Estimate 11.1%
Adult obesity prevalence (age-standardized, %) 1990 Estimate 10.9%

Shared periods

Side by side

25 periods are published for both series in Andorra as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) Adult obesity prevalence (age-standardized, %)
2000 0% WHO 13.5% WHO
2001 0% WHO 13.9% WHO
2002 0% WHO 14.2% WHO
2003 0% WHO 14.6% WHO
2004 0% WHO 14.9% WHO
2005 0% WHO 15.3% WHO
2006 0% WHO 15.6% WHO
2007 80% WHO 15.9% WHO
2008 86% WHO 16.2% WHO
2009 82% WHO 16.4% WHO
2010 86% WHO 16.6% WHO
2011 82% WHO 16.7% WHO
2012 89% WHO 16.8% WHO
2013 91% WHO 16.9% WHO
2014 90% WHO 16.9% WHO
2015 88% WHO 17% WHO
2016 90% WHO 17% WHO
2017 94% WHO 17% WHO
2018 95% WHO 17% WHO
2019 97% WHO 17% WHO
2020 93% WHO 17% WHO
2021 97% WHO 17.1% WHO
2022 96% WHO 17.1% WHO
2023 96% WHO 17.1% WHO
2024 97% WHO 17.1% WHO

Provenance

Where these numbers come from

Measles-containing-vaccine second-dose (MCV2) immunization coverage (%)

The percentage of children who have received two doses of measles-containing vaccine (MCV2) in a given year, according to the nationally recommended schedule, based on WHO/UNICEF Estimates of National Immunization Coverage (WUENIC).

26 observations charted in Andorra · source organisations: WHO

Adult obesity prevalence (age-standardized, %)

Percentage of adults aged 18 and older with a body mass index (BMI) of 30 kg/m² or higher, age-standardized estimate.

35 observations charted in Andorra · source organisations: WHO

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related